Solesence, Inc ((SLSN)) has held its Q1 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Solesence, Inc.’s latest earnings call painted a transitional quarter marked by short‑term financial pressure but clear signs of operational progress. Management acknowledged weaker revenue and a swing to losses, yet emphasized improving margins, a robust order book, and new technologies as reasons for cautious optimism about the rest of 2026.
Gross Margin Improvement
Solesence’s most notable bright spot was a 300‑basis‑point jump in gross margin to 26% in Q1 2026, up from roughly 23% a year earlier. Management credited better labor efficiency and the elimination of product quality‑related waste, suggesting that operational tweaks are beginning to translate into structural profitability gains.
Healthy Shipped and Open Orders
Despite softer reported revenue, the company highlighted a strong demand pipeline with shipped and open orders totaling $47 million. This book of business is slated for delivery within the year, giving investors visibility into near‑term top‑line potential even as execution around fulfillment remains a key focus.
New Proprietary Technologies Launched
The quarter also showcased innovation, with Solesence launching two proprietary technologies, Chromalum and WHSPR. These platforms expand its SPF‑infused hybrid offerings and open adjacencies such as hair and scalp care, broadening the company’s addressable market and deepening its technology moat.
Long-Term Growth and Market Milestones
Management reminded investors of Solesence’s longer‑term trajectory, noting a compounded annual growth rate above 50% over the past six years. Over that period, the company uplisted to NASDAQ and increased its market capitalization more than fivefold, underscoring the scale of its expansion despite current growing pains.
Operational Initiatives Underway
Under its Transform and Transcend program, Solesence is reshaping operations with updated shift structures and lean‑manufacturing training. The company is progressing on SIOP implementation, working down inventory, and pursuing facility consolidation that is expected to deliver six‑figure annual savings once fully realized.
Commercial Partnerships and Co-Marketing
On the commercial front, Solesence completed four co‑marketing activations with brand partners, including Color Science, BloomAX and Seal. These initiatives strengthen strategic relationships and showcase product‑level performance, helping to support future demand and deepen the company’s presence with key customers.
Reiterated Targets and Path to Profitability
Management reiterated full‑year targets, including a 30% gross profit margin floor for 2026 and a plan to return to double‑digit EBITDA margins by year‑end. They expect labor‑efficiency gains, SIOP‑driven inventory improvements, and savings from facility consolidation to fund this march back to profitability.
Revenue Decline Year-over-Year
Q1 2026 revenue came in at $13.0 million, down from $14.6 million a year earlier, an 11% decline. The company linked the shortfall primarily to shipment delays rather than demand softness, pointing to the sizeable order book as evidence that volumes are deferred rather than lost.
Net Income Turns Negative
Profitability took a hit, with net income swinging to a loss of $0.8 million in Q1 2026 versus a modest $0.08 million profit in Q1 2025. This roughly $0.88 million adverse shift reflects both operational disruption from the transformation program and deliberate spending in support of long‑term initiatives.
Adjusted EBITDA Deterioration
Adjusted EBITDA also weakened, moving from a positive $609,000 in Q1 2025 to a loss of $107,000 this quarter, a deterioration of about $716,000. Management framed this as temporary pressure tied to transformation investments, but it underscores the execution risk inherent in the company’s operating overhaul.
Shipment Delays and OTIF Challenges
The company’s on‑time, in‑full performance and supply alignment issues early in the quarter led to shipment delays that directly reduced reported revenue. Management attributed these disruptions to process changes during implementation of new systems, emphasizing that correcting OTIF is central to unlocking the $47 million order backlog.
Profitability Pressure from Investments
Solesence acknowledged that intentional early‑stage investments under Transform and Transcend weighed on near‑term profitability. Updated shift structures, expanded training, and operational reorganization increased expenses in the short run, but are intended to lay the foundation for more scalable and efficient growth.
Rising Complexity and Execution Risk
The earnings call also highlighted increased operating complexity as Solesence evolves its business model. Management conceded that new systems such as SIOP and facility consolidation raise execution risk, but argued that these changes are necessary to support the company’s expanded scale and product breadth.
Forward Guidance and Outlook
Looking ahead, Solesence reaffirmed its 2026 framework under Transform and Transcend, including the 30% gross profit margin floor and a target of at least 10% EBITDA margins by year‑end. With a $47 million order book, continued >50% multi‑year CAGR, and progress on three of four strategic pillars, management signaled confidence that current headwinds are transitional rather than structural.
Solesence’s latest earnings call balances near‑term softness with longer‑term promise, blending margin gains and a strong pipeline with clear execution challenges. For investors, the story hinges on whether management can convert operational initiatives into sustained profitability, but the company’s growth record and technology launches keep the narrative cautiously constructive.